Enregistrement - Lobbyistes salariés d'entreprises

Objets

• Budget
• Développement économique
• Marchés publics
• Propriété intellectuelle
• Recherche et développement
• Santé

Détails sur l'objet

Politique ou Programme

• Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.
• Canada’s Access to Medicines Regime (CAMR), certified under the Patent Act, which allows developing countries to access drugs at a lower cost, with regard to ensuring that Intellectual Property rights and anti-diversion mechanisms continue to be respected.
• Engage the Government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.
• Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy
• National Immunization Strategy. Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada.
• Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB are consistent with the mandate assigned by Parliament.
• Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework.
• Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage. Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts.
• The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada. Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR.
• The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004. Advocacy for ways to increase access to medicines and vaccines for Canadian patients.

Politique ou Programme, Proposition législative, Projet de loi ou résolution, Règlement

• Canada-European Union Comprehensive Economic Trade Agreement with respect to strengthening Intellectual Property Protection provisions under the Patent Act and related regulations.
• Legislation, regulations, policies and programs concerning the federal government's response to COVID-19, including pandemic preparedness, pharmaceutical and vaccine supply-chain management, and general administration of justice.

Politique ou Programme, Règlement

• Drug Re-importation - Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level re-importation legislation.

Politique ou Programme, Subvention, Contribution ou autre avantage financier

• Engagement with the Government regarding the Strategic Innovation Fund
• FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario

Proposition législative, Projet de loi ou résolution

• Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process. Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions.

Proposition législative, Projet de loi ou résolution, Règlement

• Canada-Europe Comprehensive Economic and Trade Agreement - Intellectual Property Provisions

Règlement

• Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment. Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development.

Techniques de communication

• Communication écrite
• Communication orale

Institutions gouvernementales

• Agence de la santé publique du Canada (ASPC)
• Chambre des communes
• Conseil d'examen du prix des médicaments brevetés (CEPMB)
• Développement économique Canada pour le Pacifique (PacifiCan)
• Emploi et Développement social Canada (EDSC)
• Finances Canada (FIN)
• Innovation, Sciences et Développement économique Canada (ISDE)
• Justice Canada (JC)
• Patrimoine canadien (PCH)
• Santé Canada (SC)
• Sénat du Canada

Adresse :
100 Milverton Drive, Suite 800
Mississauga, ON  L5R 4H1
Canada

Numéro de téléphone : 905-819-3000

Renseignements sur la société mère